Ardelyx Q2 2023: IBSRELA rev $18.3M (+61% QoQ), net loss $17.1M, FY23 guidance $72-77M

ARDELYX, INC.

2023-Q2 EPS reported -$0.21 revenue$33,702,000

IBSRELA net sales $18.3M in Q2 2023, up 61% QoQ from $11.4M in Q1.
Total revenues $22.3M (incl $4.0M licensing); net loss $17.1M ($0.08/sh) narrowed from $26.9M loss in Q2 2022.
FY2023 IBSRELA net sales guided to $72-77M; management sees $500M+ peak sales potential.
XPHOZAH NDA under FDA review (PDUFA Oct 17, 2023); launch prep underway for Q4 2023 pending approval.
Cash $127.6M at June 30, 2023; raised $11.6M via ATM in Q2.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ARDELYX, INC. reported second quarter ended June 30, 2023 results: revenue $22.3 million. Guidance raised.

Period: second quarter ended June 30, 2023
Revenue: $22.3 million
Guidance: raised
Result: reported results

Exact text from the filing

for IBSRELA were $18.3 million during the quarter ended June 30, 2023, compared to $1.6 million for the quarter ended June 30, 2022. Total revenues for the second quarter were $22.3 million, which included $4.0 million of product supply and licensing related revenue compared to $1.0 million in product supply and licensing related revenue in the same period in 2022.

View on SEC.gov

Browse all earnings releases →

ARDELYX, INC. filing history →

Source: SEC EDGAR

accession 0001628280-23-026568

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.